Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Koch

Endocrinology, Diabetes & Metabolism Roanoke, VA Medical Doctor

NPI 1558355719 CMS profile 115422

612 S Jefferson St, St 300, Roanoke, VA 24011

Open in the dashboard

General payments

$54,877

534 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Koch of Roanoke, VA is reported in the CMS Open Payments database as having received $54,877 across 534 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21 1
2024 General $22 1
2023 General $914 47
2022 General $1,640 104
2021 General $2,809 97
2020 General $8,100 106
2019 General $41,370 178

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Koch
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Michael Koch were reported at $21. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Michael Koch Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $41,370 $494 $123–$2,253 $163
2020 $8,100 $335 $85–$1,841 $114
2021 $2,809 $398 $88–$1,981 $132
2022 $1,640 $364 $88–$1,568 $149
2023 $914 $420 $113–$1,614 $160
2024 $22 $440 $121–$1,646 $164
2025 $21 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $33,144 91 payments
  2. AbbVie, Inc. $9,766 40 payments
  3. Janssen Pharmaceuticals, Inc $5,387 17 payments
  4. Dexcom, Inc. $953 52 payments
  5. Abbott Laboratories $781 51 payments
  6. Amgen Inc. $548 35 payments
  7. Medtronic, Inc. $400 13 payments
  8. Medtronic MiniMed, Inc. $372 11 payments
  9. Lilly USA, LLC $361 27 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $290 18 payments
  11. Other $2,874 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,678 21 payments
  2. Food and Beverage $8,486 495 payments
  3. Travel and Lodging $6,699 16 payments
  4. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. Tresiba $19,576 29 payments
  2. Ozempic $10,499 52 payments
  3. INVOKANA $5,387 17 payments
  4. Synthroid Endocrinology $4,701 9 payments
  5. SYNTHROID Immunology $4,003 16 payments
  6. Xultophy 100/3.6 $1,831 2 payments
  7. RYBELSUS $702 36 payments
  8. Prolia $461 29 payments
  9. EVENITY $431 27 payments
  10. Dexcom G6 Transmitter $354 18 payments
  11. Other $6,641 407 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

34

Median for Internal Medicine: 777

Drug cost

$326

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 22 $192
Metoprolol Succinate Generic 12 $133

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $11
$11 — —
Prolia
  • Amgen Inc. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record